List of Excipients in Branded Drug CARBON DIOXIDE OXYGEN MIXTURE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
General Air Service & Supply Co	CARBON DIOXIDE OXYGEN MIXTURE	carbon dioxide oxygen mixture	21220-156	CARBON DIOXIDE
Spec Connection International Inc	CARBON DIOXIDE OXYGEN MIXTURE	carbon dioxide oxygen mixture	54776-004	CARBON DIOXIDE
AGL Inhalation Therapy Co	CARBON DIOXIDE OXYGEN MIXTURE 5/95	carbon dioxide oxygen mixture 5/95	17575-020	CARBON DIOXIDE

Carbon Dioxide Oxygen Mixture: Excipient Strategy, Regulatory Pathway, Patent Risk, and Commercial Opportunities

Last updated: September 24, 2026

Carbon dioxide oxygen mixture is a medicinal-gas product rather than a conventional pharmaceutical dosage form. Its commercial value depends on gas composition, therapeutic indication, delivery device, container system, and jurisdiction. Conventional excipients generally have no role. The strongest opportunities are in validated gas blending, delivery hardware, combination-device control, hospital supply, and indication-specific clinical positioning.

What is a carbon dioxide oxygen mixture?

A carbon dioxide oxygen mixture contains oxygen and carbon dioxide in defined proportions. The best-known formulation is carbogen, commonly composed of 95% oxygen and 5% carbon dioxide, although commercial and investigational mixtures may use different concentrations.

The product may be administered through:

• Face masks and breathing circuits
• Ventilators
• Hyperbaric or specialized respiratory systems
• Laboratory or clinical perfusion equipment
• Controlled-environment medical devices

The pharmacologic effect depends on concentration and route. Oxygen supports tissue oxygenation. Carbon dioxide increases ventilatory drive and can affect cerebral and retinal blood flow through respiratory and vascular mechanisms. At excessive concentrations, carbon dioxide causes respiratory distress, acidosis, loss of consciousness, and death. Product development therefore requires tight control of composition, flow rate, pressure, and exposure time.

The term “carbon dioxide oxygen mixture” does not identify one standardized drug product. Regulatory status, patent exposure, and commercial potential vary by formulation and intended use.

Does a carbon dioxide oxygen mixture use conventional pharmaceutical excipients?

No. A medicinal gas mixture normally does not use tablets, solvents, preservatives, surfactants, suspending agents, or stabilizers. Oxygen and carbon dioxide are the active medicinal components. The relevant inactive-product strategy is usually the container-closure and delivery system.

Potentially relevant materials include:

Product component	Commercial and regulatory function
Oxygen	Active medicinal gas
Carbon dioxide	Active medicinal gas
Cylinder interior	Maintains gas purity and pressure
Valve and regulator	Controls flow, pressure, and dose delivery
Tubing and mask	Delivers the mixture to the patient
Seals and elastomers	Prevent leakage and contamination
Moisture-control components	Limit water-related corrosion or compositional drift
Label and tamper system	Supports traceability and safe use
Mixing manifold	Produces the specified gas ratio
Sensor and monitoring system	Confirms oxygen, carbon dioxide, pressure, and flow

This changes the development strategy. The central formulation questions are gas purity, blending accuracy, stability in storage, adsorption or permeation, material compatibility, and delivery performance. The central intellectual-property questions concern the mixture ratio, manufacturing process, regulator architecture, sensing controls, and use in a defined clinical setting.

What excipient strategy is commercially relevant?

Cylinder and valve materials

The gas must remain within specification throughout its labeled shelf life. Product developers should evaluate:

• Aluminum or steel cylinders
• Internal surface treatment
• Valve metals and coatings
• Elastomer compatibility
• Lubricant contamination
• Particulate generation
• Pressure cycling
• Corrosion and moisture tolerance

Oxygen creates flammability and ignition risks. Equipment used with oxygen must be compatible with oxygen service. Hydrocarbon-based lubricants, contaminated fittings, and unsuitable polymers can create safety hazards.

Carbon dioxide can interact with moisture and may contribute to corrosion or compositional instability. Water content should be controlled because moisture can affect cylinder interiors, valves, and gas analysis.

Delivery-system materials

The delivery pathway can affect dose accuracy and patient safety. Development should assess:

• Medical-grade tubing
• Mask materials
• Breathing-bag composition
• Flow-meter accuracy
• Regulator dead volume
• Gas permeability
• Adsorption of carbon dioxide
• Exhaled-gas rebreathing
• Connection standards
• Single-use versus reusable components

For products intended for home or ambulatory use, the delivery device may represent the primary commercial differentiator. A cylinder containing a known gas mixture has limited differentiation if competing suppliers provide the same composition. A validated delivery platform can create stronger customer retention and more defensible claims.

Moisture and contamination controls

The gas should be tested for water, hydrocarbons, particulates, carbon monoxide, nitrogen oxides, and other contaminants relevant to oxygen service and the intended route. The applicable pharmacopoeial monograph and national standard determine the precise specification.

The product should be evaluated for:

• Gas-ratio drift over time
• Cylinder-to-cylinder variability
• Residual gas after filling
• Cross-contamination during filling
• Valve leakage
• Pressure loss
• Storage-temperature effects
• Sampling accuracy

A mixture with a narrow therapeutic window requires more than a release assay. Continuous process controls and validated analytical methods are likely to be commercially important.

What FDA regulatory status applies to carbon dioxide oxygen mixtures?

In the United States, medicinal gases are regulated as drugs, and manufacturing operations are subject to current good manufacturing practice requirements. FDA’s medical-gas framework includes specific requirements for production, testing, labeling, distribution, and quality systems. The final pathway depends on the product’s exact composition, indication, dosage form, manufacturing site, and labeling.

Key FDA considerations include:

Regulatory issue	Relevance
Drug classification	The gas mixture is generally regulated as a drug when intended for diagnosis, cure, mitigation, treatment, or prevention of disease
New drug application	May be required for a novel composition, indication, or unapproved clinical claim
Medical-gas certification	May apply to qualifying medical gases under FDA’s certification framework
Current good manufacturing practice	Applies to manufacturing, filling, testing, labeling, and distribution
Drug listing	Required for marketed drug products
National Drug Code	May identify a specific manufacturer, package, and product
Labeling	Must state composition, indications, warnings, storage, administration, and handling requirements
Device combination	May create additional obligations for regulators, flow controllers, sensors, or integrated delivery systems

FDA’s medical-gas requirements do not make every oxygen and carbon dioxide mixture interchangeable. A product label must support the specific composition and use. A manufacturer cannot rely on the regulatory status of oxygen alone to market a different oxygen-carbon dioxide combination for a new clinical purpose.

The Orange Book should be reviewed for the exact product and active ingredient listing. A generic Orange Book conclusion cannot be assigned to the phrase “carbon dioxide oxygen mixture” because the term does not identify a unique branded drug, dosage form, sponsor, or approved application.

What are the main therapeutic and commercial applications?

Respiratory stimulation

Carbogen has historically been studied and used in settings where carbon dioxide is intended to stimulate breathing or increase respiratory drive. Modern use depends on clinical evidence, approved labeling, and institutional protocols. The market is limited unless a sponsor establishes a clear indication and a reliable administration system.

Ophthalmology and retinal research

Carbon dioxide-containing oxygen mixtures have been used in retinal and ocular research because carbon dioxide can affect retinal and choroidal blood flow. Commercial opportunities may exist in controlled clinical research, ophthalmic procedures, or specialized diagnostic protocols. These markets are typically smaller than hospital oxygen markets but may support higher margins if the product is bundled with validated equipment and a clinical workflow.

Oncology and radiation research

Carbogen has been studied as a method to modify tissue oxygenation and tumor microenvironment conditions during radiotherapy. The scientific rationale has not automatically translated into a broad commercial drug market. A current product would require modern clinical evidence, a defined patient population, and regulatory support for any oncology claim.

Research and laboratory use

Research institutions may purchase specified gas mixtures for physiology, pharmacology, organ perfusion, tissue engineering, and controlled-atmosphere studies. Research-use products can be commercially attractive because they may avoid some clinical-use requirements, but labeling must not imply human therapeutic use.

Specialized hospital and emergency applications

Hospitals may require custom gas mixtures for respiratory therapy, anesthesia support, and specialty procedures. The business opportunity is often logistical rather than formulation-based. Suppliers compete on cylinder availability, fill accuracy, delivery reliability, service coverage, and integration with hospital gas systems.

How strong is the patent estate for carbon dioxide oxygen mixtures?

The base composition is likely to have limited patent strength when the claimed invention is only a known ratio of oxygen and carbon dioxide. Broad composition claims may face prior-art issues because carbogen and related mixtures have been known for decades.

More defensible patent categories include:

1. A narrowly defined gas ratio for a newly demonstrated indication.
2. A controlled administration protocol involving concentration, flow, pressure, and exposure time.
3. A sensor-controlled system that maintains the composition during patient use.
4. A portable or ambulatory delivery device.
5. A filling or blending process that improves accuracy or reduces contamination.
6. A combination of gas mixture and a specific ventilator, mask, chamber, or diagnostic system.
7. A method for treating a defined patient subgroup supported by clinical data.
8. A container system that limits gas-ratio drift or improves storage stability.

Patent applicants should separate composition claims from use, process, and device claims. A single patent family directed to “oxygen and carbon dioxide” is unlikely to provide durable market exclusivity unless the claims include a novel concentration range, therapeutic purpose, or technical control feature.

Patent risk is jurisdiction-specific. A product-level freedom-to-operate review should cover the United States, Europe, Japan, China, and the markets where the sponsor expects hospital sales. Patent searches should include “carbogen,” “carbon dioxide oxygen mixture,” “hypercapnic oxygen,” “respiratory gas mixture,” “medical gas blending,” and the intended clinical indication.

Are formulation patents, method-of-use patents, or manufacturing patents most valuable?

For this product category, method-of-use and device patents are generally more commercially useful than conventional formulation patents.

Patent category	Likely value
Broad oxygen-carbon dioxide composition	Low to moderate, depending on concentration and prior art
Narrow concentration range	Moderate if linked to unexpected clinical performance
Method of treatment	Moderate to high if the indication is specific and clinically supported
Delivery-device integration	High when it controls dose and improves safety
Gas blending and filling	Moderate, especially for quality and scale advantages
Sensor-based closed-loop control	High if technically novel and difficult to design around
Packaging and valve system	Moderate, with value tied to performance and regulatory validation
Research-use application	Low to moderate unless it supports a dominant platform

Method-of-use patents may also encounter patent-eligibility and enablement challenges. The claims should include measurable administration parameters and clinical outcomes, not only a broad statement that the mixture treats a disease.

What generic entry and biosimilar risks exist?

There is no conventional biosimilar risk because the product is not a biologic. Generic-entry risk is substantial if the product is an established gas mixture with a simple composition and no meaningful device differentiation.

Potential competitors include:

• Medical-gas manufacturers
• Hospital oxygen suppliers
• Specialty respiratory-product companies
• Contract gas blenders
• Device companies with integrated flow-control systems
• Research-gas suppliers

A competitor may enter by matching the gas composition while using a different cylinder, regulator, or distribution network. The strongest barriers are usually operational rather than molecular:

• Qualified filling facilities
• Medical-gas quality systems
• Hospital contracts
• Cylinder fleet and reverse logistics
• Validated analytical methods
• Regulatory approvals
• Clinical evidence
• Device interoperability
• Reliable supply during emergencies

A sponsor that owns only a composition patent may have limited protection against substitution. A sponsor that controls the gas, delivery device, monitoring software, and clinical protocol can create a more difficult competitive position.

When does carbon dioxide oxygen mixture lose exclusivity?

There is no single exclusivity date for the product category. Exclusivity depends on the specific approved product and regulatory pathway.

Potential exclusivity sources include:

• Patent terms, generally measured from the earliest effective nonprovisional filing date in the United States
• New chemical entity exclusivity, if applicable
• New clinical investigation exclusivity
• Orphan-drug exclusivity, if the product qualifies
• Pediatric exclusivity
• Device-related intellectual property
• Trade secrets covering filling, calibration, and quality-control methods

A known gas mixture may not qualify for new chemical entity exclusivity. A sponsor seeking commercial protection should build value around a new indication, controlled delivery system, clinical evidence, and manufacturing reliability rather than relying on the gas composition alone.

What licensing opportunities exist?

Licensing opportunities are most credible in four areas:

Hospital supply and distribution

A specialty-gas developer can license or contract with an established medical-gas supplier for filling, cylinder management, and regional distribution. This approach reduces capital requirements and accelerates hospital access.

Delivery-device partnerships

Device manufacturers can provide regulators, ventilators, masks, portable systems, and sensors. A combination product may use co-development, supply, or field-of-use licensing agreements.

Clinical-indication licensing

An owner of clinical data may license rights for ophthalmology, oncology, respiratory medicine, or critical care. The value depends on the strength of the evidence and whether the indication is included in approved labeling.

Research-use commercialization

Academic or biotechnology groups may license a validated gas protocol for organ preservation, tissue engineering, or experimental physiology. These agreements generally have lower regulatory risk but smaller revenue potential.

No specific licensing deal can be attributed to “carbon dioxide oxygen mixture” without identifying a defined product or patent family. The category includes multiple formulations and uses.

What are the revenue opportunities?

Revenue potential is driven by the business model rather than the cost of oxygen and carbon dioxide.

Business model	Margin profile	Main commercial requirement
Bulk hospital gas supply	Low to moderate	Scale, logistics, uptime
Specialty cylinders	Moderate	Regional service and quality assurance
Pre-mixed disposable cartridges	Moderate to high	Portable delivery and safety validation
Gas plus sensor-controlled device	High	Device clearance, software, clinical evidence
Research-use gas mixtures	Moderate	Purity, customization, fast fulfillment
Indication-specific therapeutic product	Potentially high	Clinical development and regulatory approval
Contract filling and private label	Moderate	Qualified facilities and manufacturing capacity

Revenue exposure from a branded product is difficult to estimate without an identified sponsor, approved indication, market, and annual unit volume. The base gas has low raw-material cost, so differentiation and service can determine gross margin.

What is the most attractive commercial strategy?

The strongest strategy is a combination product with:

• A tightly specified oxygen-carbon dioxide ratio
• A validated regulator or delivery system
• Real-time gas-composition monitoring
• A defined clinical or research indication
• A quality-controlled cylinder or cartridge
• A distribution agreement with an established medical-gas supplier
• Patent claims covering the device, administration method, and indication

A commodity carbogen cylinder has limited protection and faces substitution risk. A portable, sensor-controlled platform with a clinically validated protocol has greater pricing power and more defensible intellectual property.

Key Takeaways

• Carbon dioxide oxygen mixture is a medicinal gas product, not a conventional excipient-based formulation.
• Conventional excipients generally have no role; the container, valve, tubing, regulator, and sensor system are the critical product components.
• Carbogen, often 95% oxygen and 5% carbon dioxide, is a recognized example, but the commercial and regulatory analysis depends on the exact composition.
• Broad composition patents are likely weaker than patents covering delivery systems, treatment protocols, sensors, filling processes, and specific indications.
• The product is not subject to biosimilar competition, but generic and commodity medical-gas competition can be significant.
• Commercial differentiation is strongest in integrated gas-and-device systems, specialty hospital supply, and clinically validated indications.
• FDA status, Orange Book listing, exclusivity, and Paragraph IV risk must be assessed for the specific sponsor, composition, application, and NDC.
• The main manufacturing barriers are gas purity, blending accuracy, cylinder compatibility, oxygen-service safety, analytical validation, and distribution reliability.

FAQs

Is carbogen the same as a carbon dioxide oxygen mixture?

Carbogen is a type of carbon dioxide oxygen mixture. The term commonly refers to a mixture containing approximately 95% oxygen and 5% carbon dioxide, but commercial specifications can differ.

Can carbon dioxide oxygen mixtures be sold as over-the-counter products?

A medically marketed mixture generally requires a regulatory basis for its intended use. Product classification depends on labeling, concentration, route, claims, and jurisdiction. A research-use product cannot be labeled for human treatment without the applicable authorization.

Are oxygen and carbon dioxide patentable as active ingredients?

The elements themselves are not new active ingredients. Patentability may arise from a novel ratio, administration protocol, treatment indication, delivery system, sensor architecture, or manufacturing process.

Is a carbon dioxide oxygen mixture a combination product?

It may be treated as a combination product when marketed with a device that is necessary for safe or effective administration. The regulatory classification depends on the product’s primary mode of action and the role of the device.

What is the main safety concern with carbogen?

The principal risks are excessive carbon dioxide exposure, respiratory acidosis, hypoxia caused by delivery failure or incorrect composition, pressure-related injury, and oxygen-related fire hazards. Validated regulators, compatible equipment, gas monitoring, and precise labeling are essential.

References

1. U.S. Food and Drug Administration. (2017). Medical gas containers and closures: Current good manufacturing practice requirements. FDA.

2. U.S. Food and Drug Administration. (2020). Medical gases: Current good manufacturing practice and certification requirements. FDA.

3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

5. European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia. Council of Europe.

6. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21: Food and drugs. U.S. Government Publishing Office.